Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
SAN DIEGO, Nov. 05, 2024 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts highlighting clinical data from the KOMET-007 combination trial of ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, to be held in San Diego from December 7-10, 2024.
Session titles and information for the two abstracts are listed below and are now available on the ASH online itinerary planner.
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Session: 616. AML: Investigational Drug & Cellular Therapies: Menin Inhibitors in AML
Date and Time: Saturday, December 7, 2024; 2:00 - 3:30 PM PT
Oral Presentation Time: 2:45 PM PT
Location: San Diego Convention Center, Ballroom 20CD
Publication Number: 214
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET 007
Session: 616. AML: Investigational Drug & Cellular Therapies: Poster II
Date and Time: Sunday, December 8, 2024; 6:00 PM - 8:00 PM PT
Location: San Diego Convention Center, Halls G-H
Publication Number: 2880